Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Xiangya Hospital of Central South University48 Second Xiangya Hospital of Central South University37 Eli Lilly and Company37 Janssen Research & Development, LLC31
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Changsha

1154 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing
2027-11-23
Not yet open
Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support
NCT07751003COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD, Hypercapnia
Sir Run Run Shaw Hospital
Not applicable
236
Zhengzhou, Changsha, Hangzhou, Wenling
2027-08-01
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2027-01-11
Not yet open
Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications
NCT07444463Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD)
Central South University
Not applicable
400
Changsha
2027-01-01
Not yet open
Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG
NCT07918781Postoperative Atrial Fibrillation, Coronary Artery Disease
China National Center for Cardiovascular Diseases
Not applicable
1,470
Beijing, Guangzhou, Zhenzhou, Changsha, Nanjing
2026-12-01
Not yet open
Eli Lilly and Company
Phase 3
2,115
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan
2026-12
Not yet open
BrightGene Bio-Medical Technology Co., Ltd.
Phase 2
160
Changsha
2026-11-30
Not yet open
Xiangya Hospital of Central South University
Not applicable
15,400
Changsha
2026-11-30
Not yet open
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 1
60
Changsha
2026-11-29
Not yet open
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
20
Changsha
2026-11-20
Not yet open
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Phase 1
88
Changsha, Xi'an, Shanghai, Huzhou
2026-11-15
Not yet open
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
270
Fuzhou, Harbin, Changsha, Nanchang, Changchun, Shanghai, Taizhou
2026-11-01
Recruiting
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
NCT07795554Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
Second Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-11-01
Not yet open
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
NCT07909655Idiopathic Pulmonary Fibrosis (IPF)
DrugHB0056
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2
75
Changsha, Shanghai
2026-11
Not yet open
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
18
Changsha
2026-11
Not yet open
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
NCT07878871Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
DrugFurmonertinib
Hunan Province Tumor Hospital
Phase 2
27
Changsha
2026-11
Recruiting
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Phase 1
20
Changsha, Suzhou
2026-10-31
Not yet open
Amgen
Phase 2
15
Beijing, Changsha
2026-10-31
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Beijing, Chongqing, Guangzhou, Shijiazhuang, Luoyang, Changsha, Changzhou, Nanjing
2026-10-26
Recruiting
tACS for Working Memory in Schizophrenia
NCT07701343Schizophrenia, Working Memory
Central South University
Not applicable
30
Changsha
2026-10-26
Not yet open
Central South University
Not applicable
75
Fuzhou, Changsha, Yangzhou
2026-10-25
Not yet open
Clinical Trial of SEEG for Drug-resistant Epilepsy
NCT07923058Drug-Resistant Epilepsy
Beijing Pins Medical Co., Ltd
Not applicable
99
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Wuhan, Changsha, Jinan
2026-10-23
Not yet open
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
NCT07882628Pulmonary Nodules, Early Detection of Cancer, Lung Neoplasms
Beijing Chao Yang Hospital
Observational
1,050
Beijing, Changsha
2026-10-21
Not yet open
HELP Therapeutics Co., Ltd.
Phase 1/2
16
Changsha
2026-10-20
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
64
Beijing, Lanzhou, Foshan, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2026-10-20
Not yet open
LaNova Medicines Limited
Phase 1/2
90
Beijing, Xinxiang, Shiyan, Changsha, Liaocheng, Shanghai, Wenzhou
2026-10-19
Recruiting
Study of UBT37034 Injection
NCT07873645Overweight , Obesity
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 1
40
Changsha
2026-10-15
Not yet open
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
30
Changsha
2026-10-13
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin
Daiichi Sankyo
Phase 1/2
400
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Hexi District, Tianjin, Jiamusi
2026-10-13
By invitation
The Third Xiangya Hospital of Central South University
Phase 3
300
Changsha
2026-10-10
Not yet open
Online Tai Chi Versus Digital CBT-I for Chronic Insomnia
NCT07853651Chronic Insomnia Disorder
The Third Xiangya Hospital of Central South University
Not applicable
172
Changsha
2026-10-10
Recruiting
AstraZeneca
Phase 3
140
Beijing, Bengbu, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2026-10-09
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
30
Changsha
2026-10-01
Not yet open
Mundipharma (China) Pharmaceutical Co. Ltd
Observational
378
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2026-10
Not yet open
Sinovac Biotech Co., Ltd
Phase 4
150
Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan
2026-10
Recruiting
Sun Yat-sen University
Phase 3
204
Guangzhou, Changsha, Fuzhou
2026-09-29
Recruiting
AstraZeneca
Observational
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2026-09-28
Recruiting
Clarify HPP: Disease Burden of HPP Patients in China
NCT07905287Hypophosphatasia (HPP)
AstraZeneca
Observational
200
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Huai'an
2026-09-26
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
300
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Jiaxing, Jining, Kunming
2026-09-26
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan
2026-09-24
Recruiting
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
105
Guangzhou, Changsha, Shanghai, Ningbo
2026-09-24
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
30
Changsha, Shanghai
2026-09-23
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
246
Beijing, Guangzhou, Changsha, Hangzhou
2026-09-22
Not yet open
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
40
Changsha
2026-09-21
Recruiting
4D Molecular Therapeutics
Phase 3
514
Beijing, Changchun, Changsha, Haerbin, Hangzhou, Jinan, Lanzhou, Nanchang
2026-09-18
Recruiting
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-17
Recruiting
AstraZeneca
Phase 3
286
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-09-17
Recruiting
AstraZeneca
Phase 3
950
Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2026-09-16
Recruiting
AstraZeneca
Phase 3
1,330
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jiaxing
2026-09-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
300
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-09-12
Recruiting
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 3
360
Changsha
2026-09-07
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
320
Changsha, Wenzhou
2026-09-02
By invitation
Efficacy and Safety of HRS-9190 in General Anesthesia
NCT07733245Adult Participants Requiring Tracheal Intubation Under General Anesthesia for Elective Surgery
The Third Xiangya Hospital of Central South University
Phase 3
320
Changsha
2026-09-02
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
23
Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan
2026-09-01
Not yet open
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Not yet open
Study of SG301 for Renal AMR After Transplantation
NCT07764627Antibody Mediated Rejection
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
10
Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2026-09-01
Not yet open
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2026-09-01
Not yet open
Zhejiang Cancer Hospital
Phase 3
140
Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Jinan, Qingdao, Chengdu
2026-09
Not yet open
Dizal Pharmaceuticals
Phase 2/3
880
Chongqing, Harbin, Changsha, Jinan, Shanghai
2026-09
Not yet open
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Not yet open
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
NCT07833098Hypertension, Resistant Hypertension, Uncontrolled Hypertension
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 2
240
Baotou, Beijing, Changsha, Chengdu, Chongqing, Daqing, Hebei, Hengyang
2026-09
Recruiting
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian
2026-08-31
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
60
Changsha, Shanghai
2026-08-28
Recruiting
Zhuhai United Laboratories Co., Ltd.
Phase 1
94
Changsha
2026-08-26
Recruiting
Artificial Intelligence Support for Stroke
NCT07785492Ischemic Stroke, Acute
Capital Medical University
Not applicable
516
Changsha
2026-08-26
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Recruiting
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jing’an, Chengdu, Hangzhou, Beijing
2026-08-25
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity
DrugTQF3250
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
72
Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing
2026-08-25
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Baoding, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu
2026-08-24
Not yet open
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Recruiting
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Recruiting
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
98
Changsha
2026-08-20
Not yet open
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Not yet open
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes Mellitus
NCT07762625Diabetes Prevention, GDM, Lifestyle Intervention, Couples
The Third Xiangya Hospital of Central South University
Not applicable
362
Changde, Changsha, Huaihua
2026-08-15
Not yet open
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Not applicable
74
Changsha
2026-08-15
Recruiting
Hunan Province Tumor Hospital
Phase 3
186
Changsha
2026-08-12
Recruiting
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-08-10
Not yet open
Hangzhou PhecdaMed Co., Ltd.
Phase 3
300
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2026-08-03
Not yet open
Xiangya Hospital of Central South University
Not applicable
64
Changsha
2026-08-01
Recruiting
Yang Zhang
Not applicable
15
Changsha
2026-08-01
Not yet open
EEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes
NCT07760415Sepsis, Sepsis Associated Encephalopathy, Sepsis and Septic Shock, Sepsis at Intensive Care Unit
Xiangya Hospital of Central South University
Observational
78
Changsha
2026-08-01
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
240
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Changsha, Zhuzhou
2026-08
Not yet open
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Not yet open
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
NCT07780877Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 2
85
Changsha, Shanghai
2026-08
Not yet open
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
50
Changsha
2026-08
Not yet open
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT07721012Patients With Irritable Bowel Syndrome With Diarrhea
Lei Yunshang Group
Phase 2
120
Beijing, Changsha, Daqing, Guangzhou, Hohhot, Lianyungang, Luoyang, Meihekou
2026-07-31
Recruiting
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Sun Yat-sen University
Phase 3
568
Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha
2026-07-24
Recruiting
Boehringer Ingelheim
Phase 3
35
Beijing, Changsha, Shanghai
2026-07-21
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
17
Changsha
2026-07-20
Recruiting
AstraZeneca
Phase 3
915
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2026-07-16
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
80
Beijing, Hangzhou, Changsha, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan
2026-07-16
Recruiting
Central South University
Not applicable
150
Changsha
2026-07-15
Recruiting
Angitia Biopharmaceuticals Guangzhou Limited
Phase 2
48
Beijing, Shenzhen, Changsha, Suzhou, Shanghai
2026-07-14
Not yet open
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Recruiting
Safety and Efficacy of Eculizumab in High-risk TA-TMA
NCT07707687Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
DrugEculizumab
First Affiliated Hospital of Zhejiang University
Phase 2
24
Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou
2026-07-10
Recruiting
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
NCT07692841Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor
DrugG-Csf
First Affiliated Hospital of Zhejiang University
Phase 3
560
Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou
2026-07-10
Not yet open
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
NCT07674368ALK Fusion-positive Non-small Cell Lung Cancer
DrugRecaticimab
Hunan Cancer Hospital
Phase 4
29
Changsha
2026-07-10
Recruiting
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
Recruiting
AstraZeneca
Phase 3
600
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang
2026-07-06
Recruiting
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
84
Anyang, Beijing, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2026-07-05
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
472
Fuzhou, Zhengzhou, Changsha, Shenyang, Jinan, Hangzhou
2026-07-03
Not yet open
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Recurrent Implantation Failure
Peking University Third Hospital
Not applicable
878
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an
2026-07-01
Recruiting
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
DrugPrednisone
Peking Union Medical College Hospital
Phase 4
198
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai
2026-07
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
105
Changsha
2026-07
Not yet open
Xiangya Hospital of Central South University
Observational
120
Changsha
2026-07
Recruiting
Climb Bio, Inc.
Phase 1/2
30
Mianyang, Baoji, Beijing, Bengbu, Changsha, Hefei, Nanchang, Suzhou
2026-06-30
Recruiting
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
TIS for Improving Cognitive Impairment in Schizophrenia
NCT07647380Schizophrenia Disorder, Cognitive Impairments
Central South University
Not applicable
50
Changsha
2026-06-24
Recruiting
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Recruiting
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
NCT07314216NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations
DrugFurmonertinib
Hunan Cancer Hospital
Phase 2
15
Changsha
2026-06-22
Recruiting
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Recruiting
Hefei Xinzhu Biological Technology Co., Ltd.
Phase 1/2
114
Changsha, Shanghai, Zhengzhou
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
Beijing, Changsha, Chongqing, Guangzhou, Hangzhou
2026-06-11
Recruiting
AstraZeneca
Not applicable
500
Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou
2026-06-10
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Guangzhou, Changsha
2026-06-08
Not yet open
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Not yet open
AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
NCT07593170Obesity, Obese Adolescents, Obese Children and Adolescents, Akkermansia Muciniphila
Central South University
Phase 2
100
Changsha
2026-06-06
Not yet open
Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases
NCT07638709Non Small Cell Lung, Brain Metastasases
Xiangya Hospital of Central South University
Observational
150
Changsha
2026-06-05
Recruiting
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT07544056Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
DrugsBEBT-209·Gemcitabine·Carboplatin
BeBetter Med Inc
Phase 2/3
446
Guangzhou, Changsha
2026-06-04
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-06-02
Not yet open
Central South University
Not applicable
99
Changsha
2026-06-01
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
9
Changsha
2026-06-01
Not yet open
Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research
NCT07611695Pulmonary Tuberculosis, Tuberculosis (TB), Tuberculosis Active
Huashan Hospital
Observational
31,600
Changsha, Shanghai
2026-06-01
Recruiting
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
NCT07652489Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Eye & ENT Hospital of Fudan University
Observational
70
Harbin, Changsha, Shenyang, Shanghai, Xi’an, Wenzhou
2026-06-01
Not yet open
Xiangya Hospital of Central South University
Not applicable
90
Changsha
2026-06
Not yet open
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204Recurrent/Metastatic Head and Neck Cancer
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
128
Beijing, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Taiyuan, Chengdu
2026-06
Not yet open
Jiangxi Kvvit Pharmaceutical Co., Ltd.
Phase 1
83
Changsha
2026-06
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
144
Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao
2026-05-31
Not yet open
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
18
Changsha
2026-05-29
Not yet open
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1/2
17
Changsha
2026-05-25
Recruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 2
18
Changsha
2026-05-24
Recruiting
Yingyong Zhou,MD,PhD
Phase 2
200
Changsha, Chengdu
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou
2026-05-22
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
200
Changsha, Chengdu
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou
2026-05-21
Recruiting
Study on iTBS Regulating the Reward Circuit Function to Improve Anhedonia in Depression
NCT07813169Major Depression, Anhedonia, Melancholic Depression, Theta Burst Stimulation
Guo Wenbin
Not applicable
60
Changsha
2026-05-19
Recruiting
Adaptive DBS for PD
NCT07635823Parkinson Disease(PD)
Beijing Pins Medical Co., Ltd
Not applicable
60
Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu
2026-05-16
Not yet open
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients
NCT07460336Latent Autoimmune Diabetes in Adults (LADA)
DrugsCofrogliptin·Cholecalciferol·Metformin
Second Xiangya Hospital of Central South University
Not applicable
84
Changsha
2026-05-15
Not yet open
The Third Xiangya Hospital of Central South University
Phase 2
152
Changsha
2026-05-15
Not yet open
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Active, closed
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
64
Changsha
2026-05-12
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing
2026-05-11
Recruiting
Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
NCT07529626Pancreatic Tumor, Benign, Pancreatic Cancer, Adult, Pancreatic Cancer Resectable
Shanghai Zhongshan Hospital
Observational
320
Changsha, Shanghai, Xi’an
2026-05-11
Recruiting
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
NCT07608003Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse Midline, H3K27M-mutant
Xiangya Hospital of Central South University
Observational
500
Changsha
2026-05-10
Not yet open
Hunan Province Tumor Hospital
Phase 2
50
Changsha
2026-05-10
Recruiting
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2/3
330
Changsha
2026-05-09
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
By invitation
Precision Antithrombotic Therapy
NCT07654634Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
The Third Xiangya Hospital of Central South University
Observational
5,000
Changsha
2026-05-01
Not yet open
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
DrugsEtoposide and carboplatin·Limertinib
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2026-05-01
Not yet open
Prospective International Multi-center Clinical Trial of PGT-A Upgrade
NCT07533630Infertility Assisted Reproductive Technology
Reproductive & Genetic Hospital of CITIC-Xiangya
Observational
1,700
Changsha, Nanjing, Kunming
2026-05
Not yet open
Kunming Pharmaceuticals, Inc.
Phase 2
100
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou
2026-04-30
Recruiting
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
88
Changsha
2026-04-30
Recruiting
Multitude Therapeutics Inc.
Phase 2
180
Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang
2026-04-29
Recruiting
RemeGen Co., Ltd.
Phase 1/2
326
Hunan, Sichuan, Fujian, Guangdong, Guizhou, Heilongjiang, Changsha, Nanjing
2026-04-27
Recruiting
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
BioNTech SE
Phase 3
736
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang
2026-04-22
Active, closed
AstraZeneca
Not applicable
4,000
Beijing, Changlexi, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangdong Province
2026-04-21
Recruiting
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
472
Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi
2026-04-18
Recruiting
Sun Yat-sen University
Phase 3
260
Guangzhou, Changsha, Fuzhou, Hangzhou, Nanning
2026-04-16
Recruiting
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
NCT07525986Laparoscopic Surgery, Visceral Pain, Postoperative, Anrikefon, Patient-controlled Intravenous Analgesia
DrugsAnrikefon·Morphine
Peking University First Hospital
Phase 4
140
Beijing, Shenzhen, Changsha
2026-04-14
Recruiting
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
magAssist, Inc.
Not applicable
204
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Suzhou, Xi'an
2026-04-09
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Active, closed
RET-Targeted Molecular Imaging Probes in Prostate Cancer
NCT07886138Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
Xiangya Hospital of Central South University
Early Phase 1
50
Changsha
2026-04-03
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
60
Changsha
2026-04-02
Recruiting
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
Longfei Liu，MD
Phase 4
20
Changsha
2026-04-01
Recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1
60
Changsha
2026-03-30
Recruiting
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Fuzhou, Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-24
Recruiting
Amgen
Phase 3
406
Beijing, Zhengzhou, Changsha, Nanjing, Yinchuan, Xi'an, Jinan
2026-03-23
Not yet open
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Active, closed
AstraZeneca
Observational
146
Guangzhou, Shenyang, Jinan, Changchun, Changsha, Chengdu, Haikou, Kunming
2026-03-19
Recruiting
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase 2
90
Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou
2026-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
TransThera Sciences (Nanjing), Inc.
Phase 2
94
Guangzhou, Wuhan, Changsha, Nanjing, Jinan, Linyi, Hangzhou, Beijing
2026-03-17
Recruiting
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
By invitation
The Third Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-03-11
Recruiting
Simcere Pharmaceutical Co., Ltd
Phase 3
498
Xiamen, Changsha, Chengdu, Hangzhou
2026-03-11
Recruiting
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Recruiting
AstraZeneca
Observational
2,100
Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai
2026-03-06
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua
2026-03-05
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Recruiting
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Recruiting
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
76
Changsha
2026-03-02
Recruiting
Bambusa Therapeutics
Phase 1/2
64
Beijing, Guangzhou, Changsha, Nanjing, Jinan, Qingdao, Yantai, Zibo
2026-03-02
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
186
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou
2026-03-01
Not yet open
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou
2026-03-01
Recruiting
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）
NCT07368608Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
BeBetter Med Inc
Phase 1/2
340
Changsha
2026-03-01
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Recruiting
Xiangya Hospital of Central South University
Phase 4
152
Guangzhou, Changsha
2026-02-24
Recruiting
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Recruiting
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chaohu, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
Eli Lilly and Company
Phase 1
68
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
2026-02-04
Recruiting
Xiangya Hospital of Central South University
Phase 4
1,092
Changsha
2026-02-02
Recruiting
Xiangya Hospital of Central South University
Phase 3
1,062
Changsha, Chang’an, Cili, Guankou, Huayuan, Lanshan, Leiyang, Pingjiang
2026-02-01
Not yet open
MindRank AI Ltd
Phase 3
738
Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei
2026-02
Active, closed
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
DrugRis-Rez
Hansoh BioMedical R&D Company
Phase 1
40
Beijing, Fuzhou, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-01-29
Recruiting
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Not yet open
Wangjing Hospital, China Academy of Chinese Medical Sciences
Not applicable
106
Beijing, Changsha, Tianjin
2026-01-15
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
By invitation
Xiangya Hospital of Central South University
Observational
3,000
Changsha
2026-01-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Recruiting
Second Xiangya Hospital of Central South University
Observational
80
Changsha
2026-01-03
Not yet open
Stereotactic Aspiration of Brain Stem Hematoma
NCT07300501Brain Stem Hematoma
First Affiliated Hospital of Zhejiang University
Not applicable
300
Hangzhou, Changsha, Guangzhou, Jinan, Shanghai, Shenzhen, Taizhou, Wenzhou
2026-01-01
Recruiting
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
DrugsChiglitazar·Vitamin E
Shanghai Jiao Tong University School of Medicine
Phase 2
300
Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun
2026-01-01
Not yet open
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Recruiting
Sanofi
Phase 2
144
Beijing, Changsha, Hangzhou, Shanghai, Wuhan
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
Xiangya Hospital of Central South University
Not applicable
104
Changsha
2025-12-24
Recruiting
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian
2025-12-22
Not yet open
Video Intervention to Reduce Depression-related Stigma Among Adolescents
NCT07282366Depression - Major Depressive Disorder
Jian-Jun Ou
Not applicable
500
Changsha
2025-12-20
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Recruiting
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Recruiting
AstraZeneca
Phase 2
320
Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong
2025-12-15
Recruiting
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Active, closed
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
Lepu Biopharma Co., Ltd.
Phase 2
16
Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan
2025-12-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
Pfizer
Phase 3
450
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Active, closed
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Recruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 2
40
Changsha
2025-12
Recruiting
AstraZeneca
Not applicable
3,000
Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian
2025-11-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
146
Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing
2025-11-21
Recruiting
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Recruiting
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
Everest Medicines (Beijing) Co., Ltd.
Phase 1/2
94
Changsha, Nanjing, Shanghai
2025-11-17
Recruiting
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Recruiting
Second Xiangya Hospital of Central South University
Observational
2,950
Changsha
2025-10-27
Recruiting
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest
NCT06992843Cardiac Arrest, Post-cardiac Arrest Care
Xiangya Hospital of Central South University
Not applicable
1,008
Changsha
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Active, closed
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
Mobile Health and Wearable Devices for Diabetes Complication Management
NCT07129148Diabetes Mellitus Type 2, Diabetes Mellitus Complications
Second Xiangya Hospital of Central South University
Not applicable
6,000
Changsha
2025-10-01
Active, closed
Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea
NCT07667972Melasma, Rosacea, Periorbital Hyperpigmentation, Melanosis
Xiangya Hospital of Central South University
Not applicable
200
Changsha
2025-10-01
Recruiting
Sanofi
Phase 3
980
Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
283
Changsha, Chengdu, Wuhan
2025-10-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
210
Guangzhou, Wuhan, Changsha
2025-10
Not yet open
Hunan Cancer Hospital
Phase 1
12
Changsha
2025-10
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Not yet open
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
DrugMazdutide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
420
Changsha, Changzhou, Nanjing, Dalian, Shanghai
2025-09-27
Active, closed
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344Systemic Lupus Erythematosus
DrugCM355
Second Xiangya Hospital of Central South University
Not applicable
5
Changsha
2025-09-25
Recruiting
Hansoh BioMedical R&D Company
Phase 1
18
Changsha
2025-09-23
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsBirelentinib·Venetoclax
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
DrugDelamanid
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Recruiting
Sanofi
Phase 3
942
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian
2025-09-17
Recruiting
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
Pfizer
Phase 3
140
Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou
2025-09-10
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Beijing, Binhai, Changchun, Changsha, Chengdu, Chenzhou, Chifeng, Chongqing
2025-09-06
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Not yet open
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Recruiting
The Third Xiangya Hospital of Central South University
Phase 2
35
Changsha, Hengyang, Jishou
2025-08-29
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
NCT07207291Bacterial Infections, Urinary Tract Infections, Intra-Abdominal Infections, Respiratory Tract Infections
Joincare Pharmaceutical Group Industry Co., Ltd
Phase 1
66
Changsha
2025-08-22
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
Changsha
2025-08-20
Recruiting
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
Anhui Provincial Hospital
Not applicable
18
Changsha
2025-08-16
Not yet open
Jian-Jun Ou
Not applicable
60
Changsha
2025-08-15
Recruiting
Sun Yat-sen University
Phase 3
386
Guangzhou, Guilin, Sanya, Changsha, Nanjing
2025-08-15
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Active, closed
Shenzhen Shenxin Biotechnology Co., Ltd
Phase 2
500
Changsha
2025-08-13
Recruiting
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Active, closed
AstraZeneca
Phase 3
212
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
A Study of YL202 in Patients With Advanced Solid Tumors
NCT07202364Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
DrugYL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Changsha
2025-08-04
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
24
Changsha
2025-08-04
Recruiting
Real World Evidence Study of SYN023 in Children Exposed to Rabies
NCT07327307Rabies Post-exposure Prophylaxis
Synermore Biologics (Suzhou) Co., Ltd.
Observational
232
Beijing, Shenzhen, Changsha, Hengyang, Nanchang
2025-08-02
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Recruiting
SightGlass Vision, Inc.
Not applicable
175
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2025-08-01
Not yet open
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Not yet open
Xiangya Hospital of Central South University
Phase 4
606
Changsha
2025-08
Not yet open
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 2
55
Changsha
2025-08
Active, closed
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Recruiting
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Not yet open
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xi’an, Hangzhou
2025-07-31
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
DrugsTafolecimab·Ivonescimab·Etoposide·Sintilimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai
2025-07-30
Recruiting
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Recruiting
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Beijing, Quanzhou, Luoyang, Xinxiang, Zhengzhou, Changsha, Shaoyang, Nanjing
2025-07-24
Recruiting
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 3
240
Guangzhou, Changsha
2025-07-23
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Recruiting
DualityBio Inc.
Phase 2
750
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou
2025-07-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
Bristol-Myers Squibb
Phase 3
426
Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai
2025-07-10
Recruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
By invitation
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2025-07-10
Recruiting
Shenghua Zhou
Not applicable
3,500
Changsha
2025-07-09
Recruiting
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Active, closed
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou
2025-07-02
Recruiting
Central South University
Phase 3
400
Zhumadian, Changsha, Yueyang, Dali, Xiangshan
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
DrugNSAIDs
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Not yet open
Wen-zhao ZHONG
Phase 2
134
Guangzhou, Changsha, Hangzhou
2025-07
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Recruiting
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Active, closed
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
Ming-Yuan Chen
Phase 2
208
Guangzhou, Zhongshan, Zhuhai, Changsha
2025-06-24
Recruiting
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
240
Hefei, Beijing, Changsha
2025-06-21
Recruiting
GlaxoSmithKline
Phase 3
981
Haikou, Changsha, Chengdu, Beijing, Changchun, Chongqing, Dongguan, Fuyang
2025-06-20
Recruiting
Pfizer
Phase 2
620
Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an
2025-06-19
Active, closed
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Recruiting
IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
NCT07034664Crohn's Disease, Guselkumab, Intestinal Ultrasound, Predictor
The Third Xiangya Hospital of Central South University
Observational
50
Changsha
2025-06-16
Recruiting
Bristol-Myers Squibb
Phase 3
274
Beijing, Wuhan, Changsha, Jining Shi, Tianjin
2025-06-13
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Guangzhou, Changsha, Changchun, Shanghai, Ürümqi, Hangzhou
2025-06-09
Active, closed
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
15
Fuzhou, Changsha
2025-06-09
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
48
Changsha
2025-06-05
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha
2025-06-04
Recruiting
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Recruiting
The Third Xiangya Hospital of Central South University
Observational
60
Changsha
2025-06-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
DrugsIndomethacin·Diclofenac
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Recruiting
Central South University
Observational
500
Changsha
2025-06-01
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
418
Changsha
2025-06-01
Recruiting
Xiangya Cardiopulmonary Health and Disease Cohort
NCT06972784Respiratory Function Tests，Heart Function Tests, Cardiopulmonary Function
Xiangya Hospital of Central South University
Observational
30,000
Changsha
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, Ürümqi
2025-06-01
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
236
Changsha
2025-06-01
Recruiting
Central South University
Observational
200
Changsha
2025-06-01
Recruiting
Genemagic Biosciences Co., Ltd
Early Phase 1
10
Changsha
2025-05-29
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
The Second Hospital of Anhui Medical University
Not applicable
166
Hefei, Changsha
2025-05-29
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
220
Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu
2025-05-20
Recruiting
Xiangya Hospital of Central South University
Observational
900
Changsha
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai
2025-05-16
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
566
Guangzhou, Changsha
2025-05-15
Recruiting
A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data
NCT07126821Brain (Nervous System) Cancers, Brain Arterial Disease, Neuro-Degenerative Disease, Brain Tumors
Xiangya Hospital of Central South University
Observational
100,000
Changsha
2025-05-15
Recruiting
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Changsha, Hangzhou, Beijing
2025-05-15
Active, closed
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase 3
560
Cangzhou, Changde, Changsha, Chengdu, Chongqing, Ch’ang-ch’un, Dalian, Deyang
2025-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Guangzhou, Changsha, Shanghai, Kunming
2025-05-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Active, closed
Central South University
Not applicable
108
Changsha
2025-05-08
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
172
Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha
2025-05-07
Recruiting
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Recruiting
Guangzhou 8th People's Hospital
Not applicable
210
Guangzhou, Shenzhen, Shijiazhuang, Changsha, Wenzhou, Beijing
2025-05-03
Recruiting
Hunan Cancer Hospital
Not applicable
286
Changsha
2025-05-01
Recruiting
Central South University
Observational
600
Changsha
2025-05-01
Not yet open
Hunan Province Tumor Hospital
Phase 3
94
Changsha
2025-05-01
Recruiting
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
135
Changsha
2025-04-30
Recruiting
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
669
Beijing, Chongqing, Guangzhou, Shijiazhuang, Changsha, Xuzhou, Shanghai, Xianyang
2025-04-30
Recruiting
Jian-Jun Ou
Not applicable
12
Changsha
2025-04-29
Recruiting
Region Skane
Observational
1,500
Changsha
2025-04-28
Recruiting
Nanjing Chia-tai Tianqing Pharmaceutical
Not applicable
104
Changsha
2025-04-27
Recruiting
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
NCT06974812Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
250
Fuzhou, Changsha, Shanghai
2025-04-18
Recruiting
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
Epygenix
Phase 3
260
Changsha, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Recruiting
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
Shanghai Zhongshan Hospital
Phase 2
90
Changsha, Shanghai
2025-04-03
Recruiting
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Recruiting
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
The Third Xiangya Hospital of Central South University
Observational
2,000
Changsha
2025-04-01
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
5,000
Changsha
2025-04-01
Recruiting
Sir Run Run Shaw Hospital
Phase 2
70
Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Not yet open
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Not yet open
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
110
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
DrugsOlverembatinib·Blinatumomab·Daunorubicin·Cytarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
Jianmin Pharmaceutical Group Co., LTD.
Phase 2
216
Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou
2025-03-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
Interleukin-2 for Refractory Chronic Spontaneous Urticaria
NCT06924762Chronic Spontaneous Uriticaria
Second Xiangya Hospital of Central South University
Phase 2/3
124
Changsha
2025-03-19
Recruiting
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Not yet open
Xiangya Hospital of Central South University
Phase 1/2
10
Changsha
2025-03-12
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
DrugsAsparaginase·Homoharringtonine·Dasatinib·Daunorubicin
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
Xiangya Hospital of Central South University
Observational
1,000
Changsha
2025-03-11
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an
2025-03-07
Recruiting
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
By invitation
Sinocare
Observational
120
Changsha
2025-03-04
Recruiting
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
DrugsAsparaginase·Blinatumomab·Daunorubicin·Cytarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
5,000
Changsha
2025-03-01
Recruiting
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Active, closed
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
NCT06840704Non Small Cell Lung Cancer, Small Cell Lung Cancer
Hunan Cancer Hospital
Phase 3
121
Changsha, Chenzhou, Hengyang, Yueyang
2025-02-25
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DrugsAWT020·Taxol·Pemetrexed·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Bengbu, Jiangmen, Xingtai, Harbin, Luohe, Changsha, Nanjing, Nantong
2025-02-20
Recruiting
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Recruiting
Tang-Du Hospital
Phase 2
27
Changsha, Yinchuan, Xi'an
2025-02-18
Active, closed
Gan & Lee Pharmaceuticals.
Phase 3
580
Changsha
2025-02-18
Active, closed
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian
2025-02-10
Recruiting
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Active, closed
Changes in Fat and Muscle Tissue Function and Their Impact on Metabolic Health After Bariatric Surgery
NCT07035483Obesity and Obesity-related Medical Conditions, Sarcopenic Obesity, Adipose Tissue, Abdominal
Shaihong Zhu
Observational
120
Changsha
2025-01-18
Recruiting
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
NCT06823427Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
Drugs9MW2821·JS001·Toripalimab
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
60
Changsha, Nanjing
2025-01-17
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
200
Changsha
2025-01-15
Recruiting
Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study
NCT06755840Sleep Disordered Breathing (SDB), Sleep Apnea, Cardiometabolic Diseases, Multimorbidity
Xiangya Hospital of Central South University
Observational
15,000
Changsha
2025-01-15
Recruiting
The Third Xiangya Hospital of Central South University
Not applicable
200
Changsha
2025-01-15
Rows per page Showing 1–500 of 1154
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/changsha

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,154 of those studies with a site in Changsha.

How many clinical trials are recruiting in Changsha?

661 of the 1,154 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 110 have not yet opened recruitment, 360 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changsha), 1,154 studies
PhaseStudiesRecruitingShare
Phase 344020538.1%
Phase 219310416.7%
Observational1389612%
Not applicable1308511.3%
Phase 1107739.3%
Phase 1/291667.9%
Phase 2/330202.6%
Phase 423112%
Early Phase 1210.2%

Most active sponsors

Lead sponsors with the most studies (Changsha)
Lead sponsorStudiesRecruiting
AstraZeneca13971
Xiangya Hospital of Central South University4830
Eli Lilly and Company3721
Second Xiangya Hospital of Central South University3728
Janssen Research & Development, LLC3110
The Third Xiangya Hospital of Central South University2618
Hoffmann-La Roche246
Hunan Province Tumor Hospital2317
Pfizer2211
Sanofi218
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.